Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis

Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis

Current multiple sclerosis (MS) treatments reduce relapse activity but have limited impact on disease progression. Clinical trials targeting progression often fail because of insufficient understanding of its underlying mechanisms. This study analyzed a clinically well-characterized MS autopsy cohort from the Netherland Brain Bank (186 individuals) from which we selected donors exhibiting opposite disease trajectories of slow versus rapid progre…

New AI tool accurately detects transition from RRMS to SPMS

A new machine learning tool, a form of artificial intelligence (AI), may accurately detect the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) — and may […] The post New AI tool accurately detects transition from RRMS to SPMS appeared first on Multiple Sclerosis News Today.

New Biomarker Predicts MS Progression

Researchers have identified a new biomarker in multiple sclerosis (MS): the thickness of the inflammatory rim surrounding brain lesions predicts how quickly and severely the disease progresses. By combining PET imaging and post-mortem brain analysis, the study showed that thicker rims lead to more aggressive brain damage.

The discovery will accelerate drug development and help target treatment for MS patients.